Survival and risk factors of mortality among patients with TB/HIV coinfection in Kigali City, Rwanda: a retrospective cohort study (2019–2024)

Didier Ndabana, Solange Nikwigize, Felix Murego, Jerome Ndayisenga, Patrick Migambi, Amanuel Kidane Andegiorgish · 2026

Read Survival and risk factors of mortality among patients with TB/HIV coinfection in Kigali City, Rwanda: a retrospective cohort study (2019–2024) by Didier Ndabana, Solange Nikwigize, Felix Murego, Jerome Ndayisenga, Patrick Migambi, Amanuel Kidane Andegiorgish (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13471299.txt.

Introduction

Ndabana and colleagues charted survival in 2026 among patients fighting both tuberculosis and HIV in Kigali, Rwanda, where this coinfection's death pattern had never been mapped. The study followed 1,966 patients aged 15 and over at 48 clinics from 2019 to 2024. All were on HIV therapy when tuberculosis treatment began. Survival was estimated to 168 days, and hazard models weighed what predicted death.

Mortality was high and front-loaded. About 13 percent of patients died, 264 people. Nearly four in five deaths struck within the first 56 days. Overall survival sat near 87 percent. The strongest death predictors were other chronic diseases, tripling the hazard, and undernutrition, close behind. Low CD4 counts and age over 45 each more than doubled risk. Missing preventive therapies for tuberculosis or other infections raised risk substantially. So did patchy adherence to HIV drugs and tuberculosis outside the lungs. The authors urge intensive support in the first two months, when patients die fastest.

Catalog record

CREATORDidier Ndabana, Solange Nikwigize, Felix Murego, Jerome Ndayisenga, Patrick Migambi, Amanuel Kidane Andegiorgish
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13471299

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Survival and risk factors of mortality among patients with TB/HIV coinfection in Kigali City, Rwanda: a retrospective cohort study (2019–2024) Authors: Didier Ndabana, Solange Nikwigize, Felix Murego, Jerome Ndayisenga, Patrick Migambi, Amanuel Kidane Andegiorgish Published: 2026 ABSTRACT AbstractBackgroundTuberculosis (TB) is still the most common cause of mortality among people living with HIV (PLHIV) worldwide. However, in Rwanda, no study has specifically assessed the survival and risk factors for mortality among patients with TB/HIV co-infection in urban settings such as Kigali city. This study aims to determine the survival probability and identify risk factors for mortality among patients with TB/HIV coinfection in Kigali City, Rwanda.MethodsA retrospective cohort study was conducted among 1,966 patients aged (≥ 15 years) with TB/HIV co-infection who were receiving antiretroviral therapy (ART) at the time of TB diagnosis and were enrolled at the initiation of treatment for drug-susceptible tuberculosis at 48 health facilities in Kigali between July 2019 and March 2024. Data were extracted from the e-TB system and patients’ medical records. The survival probability up to 168 days was estimated via the Kaplan–Meier method. Cox proportional hazards regression was used to predict mortality. Statistical significance was set at p < 0.05.ResultsThe median age of the patients was 39 years (IQR: 33–46), and 66.0% were male. A total of 264 patients (13.4%, 95% CI: 11.9–15.0) died, and 78.8% of the deaths occurred within the first 56 days of follow-up. The overall survival probability was 86.6% (95% CI: 84.9–88.0). Significant predictors of mortality included age ≥ 45 years (adjusted hazard ratio [aHR] = 2.21; 95% CI: 1.18–4.11), no receipt of cotrimoxazole preventive therapy (CPT) (aHR: 1.65; 95% CI: 1.29–2.13), the presence of comorbidities(including diabetes mellitus, hypertension, asthma, chronic liver disease, chronic kidney disease, malignancy, and other chronic illnesses) (aHR: 3.18; 95% CI: 2.27–4.45), no receipt of tuberculosis preventive treatment (TPT) (aHR: 1.87; 95% CI: 1.38–2.54), undernutrition (aHR: 2.72; 95% CI: 2.12–3.50), fair ART adherence (aHR: 1.89; 95% CI: 1.25–2.87), low CD4 count < 200 cells/mm³ (aHR: 2.30; 95% CI: 1.74–3.05) and extrapulmonary TB (aHR: 1.62; 95% CI: 1.15–2.28).ConclusionMortality among patients with TB/HIV-coinfected in Kigali remains high, particularly during the early treatment period. Predictors of mortality included older age, lack of TPT and CPT, comorbidities, undernutrition, fair ART adherence, low CD4 count and extrapulmonary TB. Increasing TB/HIV integrated care through improved adherence support, nutritional supplementation, comorbidity management, increased uptake of cotrimoxazole and TPT, and timely interventions are critical to reduce mortality.Clinical trial numberNot applicable.Keywords: Tuberculosis, TB/HIV coinfection, Mortality, Survival analysis, Rwanda Background Tuberculosis (TB) and human immunodeficiency virus (HIV) are still two of the most important public health problems worldwide and carry a heavy burden [1]. The dual burden of these diseases exacerbates the disease burden, leading to increased morbidity and mortality in affected populations [2]. TB is currently the leading cause of death among people living with HIV and was responsible for approximately 30% of all AIDS-related deaths worldwide in 2019, accounting for approximately 208,000 fatalities [3]. The highest burden occurs in the African and Southeast Asian regions, with 82% of the combined total TB deaths in people without HIV and people living with HIV (PLWH) [2]. In 2020, the estimated annual TB incidence in the sub-Saharan Africa region was 220 per 100,000 people, although PLWH were found to have a significantly higher incidence rate, approximately 2,279 per 100,000 per year [1]. A systematic review and meta-analysis revealed that the overall HIV prevalence among TB patients in the sub-Saharan region was 31.8%, with variations by subregion: southern Africa, 43.7%; central Africa, 41.3%; eastern Africa, 31.1%; and western Africa, 25.5% in 2019 [4]. The interaction between TB and HIV is bidirectional, as one disease can directly affect the treatment and outcomes of the other disease [4, 5]. People living with HIV are at a much greater risk for developing active TB, with estimates 15–21 times greater than those of people without HIV [6]. The reason for this increased susceptibility is attributed to the effects of HIV, which suppresses the immune response to Mycobacterium tuberculosis [6, 7]. The implementation of TB/HIV management strategies, such as TB and HIV service integration and antiretroviral therapy (ART), has progressed, yet mortality among patients with TB/HIV-coinfected remains unacceptably high in low-resource settings [8]. Like many other high-burden countries, Rwanda has made good progress in scaling up antiretroviral therapy (ART) and integrating TB/HIV services; the country has achieved high ART coverage and has implemented routine HIV testing for all TB patients and TB screening for all PLHIV [9, 10]. However, TB/HIV coinfection continues to cause considerable mortality, particularly in Kigali city [11]. Previous studies in various settings have established clinical and demographic predictors of poor outcomes among patients with TB/HIV coinfection. Immunodeficiency (CD4 < 200 cells/mm³), WHO stage IV disease, being bedridden, the absence of prophylactic drugs, old age and substance abuse are predictors of poor survival [7, 12–17]. In addition, prior studies have shown that mortality is highest in the early months of anti-TB treatment, and survival analysis studies underscore the role of timely and effective interventions for patients in the early months of treatment [13, 14]. In Rwanda, no study has assessed the survival of patients with TB/HIV-coinfected, especially in urban settings such as Kigali city, which may have different patient characteristics than rural settings do. Understanding survival and identifying risk factors associated with mortality in patients with TB/HIV-coinfected is important for improving patient management and enhancing the integration of TB/HIV collaborative care. Therefore, this study aims to determine the survival probability and identify risk factors for mortality among patients with TB/HIV coinfection in Kigali City, Rwanda. The findings are expected to help inform clinical decision-making and advance evidence-based policy development within Rwanda’s national TB and HIV programs. Methodology Study design, setting and period A retrospective cohort study involving patients with TB/HIV coinfection was carried out from July 2019 to March 2024 in Kigali city, Rwanda. Participants entered the cohort at the time of the initiation of TB treatment while already receiving antiretroviral therapy (ART). Follow-up started on the date of TB treatment initiation and continued until death, loss to follow-up, transfer-out, or treatment completion. Kigali, the capital city of Rwanda, has an estimated population of 1,745,555 million, as reported in the 2022 Census [18], and comprises three districts (Nyarugenge, Gasabo, and Kicukiro). The city has 48 health facilities providing services for the treatment of TB, which include 7 hospitals (4 district hospitals: Muhima, Nyarugenge, Kibagabaga, and Masaka; and 3 referral hospitals: CHUK, King Faisal Hospital, and Rwanda Military Hospital) and 41 health centers distributed across the three districts of Kigali (Gasabo, Kicukiro, and Nyarugenge). Each of these health facilities offers ART and has the capacity to diagnose, treat, and monitor TB patients. Study population and sampling Patients were screened for inclusion based on the following criteria: Inclusion criteria (1) Patients aged (≥ 15 years) living with HIV; (2) with documented TB/HIV coinfection; (3) already receiving ART at the time of TB diagnosis; (4) diagnosed with drug-susceptible TB; and (5) initiation of TB treatment between 1 July 2019 and 31 March 2024. Exclusion criteria (1) Patients living with HIV aged < 15 years; (2) patients not receiving ART at the time of TB diagnosis; (3) patients with multidrug-resistant TB (MDR-TB); (4) patients treated

Read the complete text